

# REMOTE RM-FCU-7B

## REFERENCES

1. SEE DRAWING 7B-I-0-3-08 - DRUG SUBSTANCE - BMS ARCHITECTURE
2. SEE DRAWING 7B-M-0-5-32 - DRUG SUBSTANCE - AFD & ID - FCU's

## NOTES



1. POWER SUPPLY (220 VAC @ 60HZ) TO REMOTES PANEL IS SCOPE OF ELECTRIC DISCIPLINE.
2. FOR 220 VAC SHALL USE RED MONOPOLAR CABLE AND BLACK MONOPOLAR CABLE RED, SIZE 2.5 MM2. FOR 24 VDC SHALL USE BLUE MONOPOLAR CABLE FOR 24 VDC(+) AND WHITE MONOPOLAR CABLE FOR VDC (-), SIZE 2.5 MM2.
3. GENERAL GROUNDING (GND) MUST BE CONNECTED TO GROUNDING BUS IN THE CONTROL PANEL INTERIOR AT BOTTOM OF THE CABINET.
4. ELECTRICAL MUST GROUNDING THE FOLLOWING: DOOR, PLATE, AND PANEL.
5. USE A SINGLE CONDUCTOR GREEN OR GREEN-YELLOW INSULATION TO CONNECT THE EQUIPMENTS WITH THE BAR BUS.
6. EACH CABLE WITHIN THE CONTROL PANEL SHALL BE PERMANENTLY TAGGED AND IDENTIFIED AT BOTH ENDS.
7. FOR ALL TERMINAL BLOCKS NUMBERS AND POINT IDENTIFICATIONS SHALL BE PERMANENTLY MARKED BY MARKING STRIPS ON TERMINAL STRIPS.
8. IDENTIFICATION SHALL BE TERMINAL BLOCK NUMBERS AND POINT NUMBERS SHOWN ON THE WIRING DIAGRAMS.
9. IS THE CONTRACTOR RESPONSIBILITY TO CONSIDER THE MISCELLANEOUS NECESSARY TO GUARANTEE ALL THE CONNECTIONS AND CORRECT INSTALLATION.

## REVISION 0 NOTES

1. INCLUSION OF THE MONITORED AND CONTROLS POINTS FOR RECTANGULAR FIRE DAMPERS.
2. UPDATE IN NUMBERS OF THE ALL SHEETS.
3. UPDATE IN ITEM DRAWINGS REFERENCE.

## REVISION 1 NOTES


1. FIXED THE ADDRESSING OF LINES BETWEEN PAGES.

 <b>TESSLER</b> engenharia							
PROJECT							
TAKEDA / BAXALTA							
CLIENT							
BURITI EPCMV PROJECT							
DOC NR							
569-DB7B-AIC-232-013							
DRAWN BY AAS		REVIEWED MAF		ENGINEER RSP		SCALE -	
						DATE 24MAY2021	

		 Empresa brasileira de hemoderivados e biotecnologia	
DRAWING TITLE			
DRUG SUBSTANCE BMS - WIRING DIAGRAM			
CLIENT NR.		REV.	
7B-I-0-3-24		1	

1	14FEB2022	ISSUE FOR CONSTRUCTION CONSIDERING COMMENTS	ACC	MAF	RSP				
0	10AGO2021	ISSUE FOR CONSTRUCTION	AAS	MAF	RSP				
A	24MAY2021	90% DD ISSUE	AAS	MAF	RSP				
	DATE	DESCRIPTION	DRAWING BY	ENGINEER	REVIEWED				







DOC NR: 569-DB7B-AIC-232-013

CLIENT NR: 7B-I-0-3-24


DRAWING TITLE:

DRUG SUBSTANCE  
BMS - WIRING DIAGRAMSHEET:  
03 OF 22REV:  
1





05.7  
05.7



DOC NR: 569-DB7B-AIC-232-013

CLIENT NR: 7B-I-0-3-24

DRAWING TITLE:  
DRUG SUBSTANCE  
BMS - WIRING DIAGRAM


SHEET:  
06 OF 22

REV:  
1










DOC NR: 569-DB7B-AIC-232-013


CLIENT NR: 7B-I-0-3-24


DRAWING TITLE:  
DRUG SUBSTANCE  
BMS - WIRING DIAGRAM

SHEET:  
09 OF 22

REV:  
1







DOC NR: 569-DB7B-AIC-232-013


CLIENT NR: 7B-I-0-3-24


DRAWING TITLE:

DRUG SUBSTANCE  
BMS - WIRING DIAGRAM

SHEET: 12 OF 22

REV: 1





TESSLER  
engenharia

ips

Takeda

Hemobrás  
Empresa brasileira de hemoderivados e biotecnologia


DOC NR: 569-DB7B-AIC-232-013


CLIENT NR: 7B-I-0-3-24

DRAWING TITLE:  
DRUG SUBSTANCE  
BMS - WIRING DIAGRAM


SHEET: 14 OF 22


REV: 1




















TESSLER

Engenharia

ips

Takeda

Hemobrás

Empresa brasileira de hemoderivados e biotecnologia


DOC NR: 569-DB7B-AIC-232-013

CLIENT NR: 7B-I-0-3-24

DRAWING TITLE: DRUG SUBSTANCE BMS - WIRING DIAGRAM

SHEET: 21 OF 22

REV: 1



DOC NR: 569-DB7B-AIC-232-013

CLIENT NR: 7B-I-0-3-24

DRAWING TITLE:  
DRUG SUBSTANCE  
BMS - WIRING DIAGRAM

SHEET: 22 OF 22

REV: 1